Recs

0

1 Big Pharma Phase 3 Failure

With all of the pipeline success we're seeing from the Big Biotech stocks lately, Big Pharma's more hit-and-miss recent drug development track record hasn't gone unnoticed.

Today, Pfizer announced that it was halting a phase 3 trial for inotuzumab ozogamicin in aggressive non-Hodgkin's lymphoma, as it wasn't showing any survival benefit over the control group. It was a surprise cancellation, and there had been a lot of enthusiasm around this drug, which targeted an antigen found in more than 90% of b-cell malignancies.

In this video, health-care analyst David Williamson discusses what this drug failure means for Pfizer, its competitors, and its investors.

Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more. 


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2445593, ~/Articles/ArticleHandler.aspx, 6/30/2015 10:16:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson
TMFGreenwave

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated 1 hour ago Sponsored by:
DOW 17,619.51 23.16 0.13%
S&P 500 2,063.11 5.47 0.27%
NASD 4,986.87 28.40 0.57%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

6/30/2015 4:00 PM
PFE $33.53 Down -0.06 -0.18%
Pfizer CAPS Rating: ****
BIIB $403.94 Up +7.73 +1.95%
Biogen Idec CAPS Rating: ****
RHHBY $35.07 Down -0.24 -0.68%
Roche Holding Ltd.… CAPS Rating: *****

Advertisement